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Voluntary medical male circumcision has been conclusively demonstrated to reduce the lifetime risk of male
acquisition of HIV. The strategy has been adopted as a component of a comprehensive strategy towards achieving
an AIDS-free generation. A number of countries in which prevalence of HIV is high and circumcision is low have
been identified as a priority, where innovative approaches to scale-up are currently being explored. Rwanda, as one
of the priority countries, has faced a number of challenges to successful scale-up. We discuss here how simplifications
in the procedure, addressing a lack of healthcare infrastructure and mobilizing resources, and engaging communities
of both men and women have permitted Rwanda to move forward with more optimism in its scale-up tactics.
Examples from Rwanda are used to highlight how these barriers can and should be addressed.
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For the first time since the beginning of the AIDS pan-
demic, the global scientific community has proposed a
means to achieve an AIDS-free generation by imple-
menting a multi-pronged, comprehensive strategy that
targets both prevention and treatment of HIV [1]. One
of the key pillars to achieving this goal includes scaling
up voluntary medical male circumcision (VMMC) in sub-
Saharan Africa. Multiple observational studies [2,3] and
randomized trials (RCTs) [4-6] have conclusively dem-
onstrated that VMMC can reduce the lifetime risk of
male acquisition of HIV by about 60% [7]. The World
Health Organization (WHO) and the Joint United Nations
Programme on HIV/AIDS (UNAIDS) have endorsed
innovative approaches to VMMC uptake in 13 priority
countries in which HIV incidence remains high, but the
prevalence of male circumcision is low [8]. Major imple-
menting agencies and international donors have agreed to
an action plan that aims to reach 80% coverage of VMMC
in these 13 countries by 2015. Successful implementation
of the plan will require performing about 20 million adult
VMMC over the next 2 years. Reaching this target is esti-
mated to avert 3.36 million new HIV infections in these* Correspondence: mutabazivincent@gmail.com
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unless otherwise stated.priority countries, for a cost savings of up to US$16.5
billion [9]. However, implementation in most of these tar-
get countries has been slow, with prevalence of VMMC
lagging far behind the goal of 80% coverage [10]. As of
2010, only 2.7% of the total number of VMMC procedures
needed to reach this coverage level had been performed,
and of all priority countries, only Kenya appears to be on
track to achieving the 80% coverage [8].
Rwanda, as one of the identified priority countries, has
set an ambitious goal of performing 700,000 additional
VMMC procedures by 2015. Sufficiently convinced by
the scientific evidence in support of VMMC, and with im-
plementation support from the WHO, UNAIDS and the
US President’s Emergency Plan for AIDS Relief (PEPFAR),
the Rwandan government is promoting VMMC as a back-
bone strategy of a comprehensive national HIV strategic
plan [11]. However, Rwanda does not have a history of
traditional circumcision, and until recently, the country
has lagged behind other priority countries. By 2014, less
than 10% of the target number of procedures had been
performed. This is in comparison to neighboring Kenya,
for example, which has achieved almost 50% VMMC co-
verage in some regions and up to 80% in others [12]. It
may be that conflicting feasibility and optimization models
for the scale-up of VMMC in Rwanda generated overly
optimistic operational targets [13].al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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As Rwanda and other priority countries embrace VMMC
scale-up, three key challenges must be addressed to sup-
port the scale-up of circumcising millions of men. These
include: 1) simplifying the VMMC procedure; 2) addres-
sing a lack of health worker infrastructure and mobi-
lizing resources in an over-burdened health system; and
3) engaging communities of men and women to com-
municate the benefits of the procedure. We discuss these
challenges here in the context of Rwanda’s experiences of
scaling up VMMC.
Simplifying the VMMC procedure
VMMC scale-up began in many of the priority countries
of sub-Saharan Africa in 2008 to 2009, with the forceps-
guided surgical method being the predominant method
of choice. There has been much discussion over the
potential cost savings associated with using a device to
increase the technical efficiency of the procedure [14].
However, there have been some concerns regarding the
high rates of adverse events (AEs) associated with some
of these devices, as well as the need for skilled operators,
which may inhibit their successful scale-up [15,16].
This has led Rwanda to consider two newer devices,
the PrePex (Circ MedTech Ltd, Israel) and the Shang
Ring (Wuhu Santa Medical Devices Technology Co
Ltd, China) devices [17]. The PrePex device is an FDA-
approved and WHO pre-qualified non-surgical device
[18]. It works by compressing the foreskin and cutting
off blood circulation, after which the distal foreskin be-
comes necrotic, permitting easy and bloodless removal
after 1 week. In the PrePex procedure, injected anesthe-
tic or sutures are not necessary, and skilled health
workers who are trained and certified can perform the
procedure in a clean, non-sterile setting [19]. Procedure
time with the PrePex device is five times faster than with
the surgical technique, and the procedure is also safer
[18]. In two cohort studies carried out in Zimbabwe and
Rwanda using trained nurses, the AE rate was 0.6 to 0.9%
in Zimbabwe [20] and 2.7%in Rwanda [18]. Expected side
effects include clear exudates, localized mild edema in the
wound area, and slough. The US Government, in partner-
ship with the Bill and Melinda Gates Foundation, is now
funding pilot evaluations in all priority African countries
using the PrePex device [19].
The Shang Ring device, yet to receive pre-qualification
by the WHO [21], involves injecting an anesthetic and
cutting of the skin, although no suturing of the incision
site is required. The device consists of an inner and outer
ring; the outer ring applies constant pressure to the fore-
skin, thus replacing the need for sutures. The device must
remain on the penis for 5 to 7 days. In RCTs in which the
Shang Ring procedure was compared with conventional
surgical procedure, AE rates related to the device werefound to be 1% [21,22]. If the Shang Ring device receives
final consideration in Rwanda, introducing variation in
the procedure method would add options for clients, and
may lead to increased demand.Addressing a lack of healthcare worker infrastructure and
mobilizing resources
Like many countries in Africa, Rwanda struggles with a
developing healthcare infrastructure, including a limited
number of physicians. Simplification of the procedure by
methods such as using devices described above, has al-
lowed for VMMC to be task-shifted to lower-tier trained
healthcare workers. Task-shifting of VMMC has been
endorsed by the WHO as a component of scale-up stra-
tegies. Although several countries have not yet adop-
ted this recommendation because of safety concerns, a
meta-analysis of VMMC procedures performed by trained
non-physician clinicians (for example nurses, midwives,
surgical aides, and clinical officers) found a frequency of
AEs similar to the rates reported when procedures were
carried out by doctors or specialists [23].
One of the most critical tasks is building a national
VMMC infrastructure with a focus on service providers.
To overcome human resource constraints, the Rwandan
government has sought to investigate task-shifting solu-
tions for non-physician clinicians in clean, non-sterile
settings, thus minimizing the burden on the healthcare
system. The first stage of the Ministry of Health VMMC
scale-up plan is to focus on 12 district hospitals, located
in all four provinces and the city of Kigali. Each hospital
has been instructed to send at least one team member
(physician or nurse) to be trained at the device centre of
excellence in Kigali. The teams will then return to their
original sites to carry out PrePex VMMC under supervi-
sion. Once this trained team member gains sufficient ex-
perience, they will become a local trainer for available
nurses at the district hospitals and surrounding health
centers in that catchment area. District hospitals will
organize the training in collaboration with the Ministry
of Health.
The first phase of this new plan is underway, with
four district hospitals trained and four more to be trained
by fall of this year. When executing the first phase, it
became clear the following factors may hinder achieve-
ment the national goal: 1) trained teams not fully dedi-
cated to the PrePex VMMC program and 2) a lack of
sufficient trainers and supervisors to allow rapid national
expansion.Engaging communities of men and women to
communicate the benefits of VMMC
Effective scale-up must include meaningful engagement
of communities in the medical benefits of VMMC. There
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ceived by men in many regions of Africa, given the low
prevalence of traditionally practiced circumcision. How-
ever, the published evidence and observations from
neighboring Uganda indicate that even in settings where
there is no prior tradition, young men are willing to
accept VMMC as a strategy to reduce HIV infection
[24]. Strategies for demand creation need to be fur-
ther developed. For example, programming that employs
community mobilization, the use of mass media, and the
inclusion of women have been shown to be effective in
Kenya [12].
There remains debate over the impact of VMMC on
behavioral disinhibition. VMMC must be accompanied
by counseling and education about maintaining consist-
ent condom use and other preventive methods. National
leadership is necessary to help educate the population
about the benefits and risks of circumcision. To over-
come this challenge, Rwanda has now initiated feasibility
and acceptability trials in children and newborn males.
Infant and child male circumcision ensures that the
wound is sufficiently healed before sexual debut, and
thus reduces the risk of HIV transmission during healing
period.Conclusions
Rwanda is facing a challenging target of 700,000 VMMC
procedures by mid 2015. A major decision for the Ministry
of Health for achieving this target while considering the
limited resources of the country has been to use PrePex
for all adult men seeking VMMC in the country. Surgi-
cal male circumcision will be only reserved to men who
are not eligible for PrePex or for males under the age of
18 years.
This is a rare and historic opportunity to be a part of
turning the tide on the pandemic of our generation, but
to take programs to scale and to maximize the impact
the intervention, an accelerated pace of service delivery
is needed. For Rwanda to achieve its targets by 2015, it
will require a bold strategy that focuses on the efficiency
of task-shifting, judicious use of resources, and the
leadership of civil society.
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